NLC and Australia’s BioCurate announce Strategic Alliance for Commercialization of New Therapies

Amsterdam, July 19, 2023

The two will collaborate on development projects to bring new therapies to market.

NLC, the European Healthtech Venture Builder based in the Netherlands, and BioCurate, an independently operated joint venture between The University of Melbourne and Monash University, announced today they have signed a Memorandum of Understanding (MoU), which paves the way for sharing of scientific and commercial expertise and collaboration on projects to bring new therapies to market.

BioCurate and NLC share complementary strengths which, when combined, could unlock vast potential for healthcare innovation. The partnership offers significant strategic value, as both share a similar mission; to transform top-tier innovations and ideas into life-changing products or services that advance health-related science.

Both companies target early-stage projects, and the partnership seeks to improve the chances of success of current and future projects in each organisation’s portfolio by improving their access to the scarce skills and resources required for the translation of scientific discoveries into commercially viable therapies.

The Hon. John Brumby AO, Chair of the BioCurate Board, said:

“We’re thrilled to expand BioCurate’s network of international strategic partners through this new agreement with NLC.

It takes a village to produce new, commercially viable therapies. This partnership helps to ensure the fantastic research taking place in Victoria’s leading academic laboratories has a better chance of becoming medicines that improve people’s lives. It also means NLC has access to the incredible talent we have in Victoria to support the success of the projects in their portfolio.”

Dr. Eric Hayes, Director of Partnerships at BioCurate, said:

“NLC was an obvious choice of partner for BioCurate because of the quality and breadth of its complementary expertise, as well as its presence in, and access to the European pharmaceutical market.

“We look forward to evaluating our combined project portfolio’s to identify specific opportunities for collaboration.”

Bert-Arjan Millenaar, CEO of NLC, commented:

“By collaborating with BioCurate, a leader in translating novel technologies to therapeutics, NLC is taking an exciting step forward in the biotech space and expands its expert network and reach to the southern hemisphere. We consider BioCurate a strategic partner for our joint mission to create novel therapies for unmet needs and we look forward to bringing science to life together.”


About BioCurate

BioCurate is a bold, collaborative venture, dedicated to delivering benefits to the community by helping to advance Australian research and innovation globally. Jointly formed by the University of Melbourne and Monash University, with support from the Victorian State Government, BioCurate identifies promising biomedical research discoveries and manages their translation into high quality pre-clinical candidates with the aim to develop potential novel human therapeutics.

BioCurate operates in the under-resourced, yet critical, early phases of therapeutic development to overcome common barriers to success and drive early decisions. BioCurate is operationally independent, with a team of experts that brings decades of scientific and commercial expertise, enabling us to recognise and realise real-world potential and providing a critical bridge between academia and industry.  Governance is provided by an experienced Board with an independent Board Chair, the Hon John Brumby AO, supported by Directors with specialist backgrounds in biotechnology, investment and corporate governance.


For any biotech-related enquiries and collaboration opportunities, please contact Lydia Kalafateli at

For any media-related requests, please contact Anne Reijns at

NLC Health Ventures Footer